Nivolumab recommended as a second-line treatment option for patients with two types of non-small-cell lung cancer
NICE draft guidance means patients with advanced squamous or non-squamous NSCLC will now be eligible for the second-line treatment on the NHS.
Published
Please sign in or register for FREE
Sign in to OnMedica
Or sign in via
Are you a GP or Specialist Doctor, practising in UK, looking for:
- easy-to-digest, relevant updates and educational content
- a safe-space to share and collaborate with peers?
OnMedica is for you, sign up FOR FREE now!
No comments yet.